Kornimate/medical-research-clean huggingface dataset:
efficacy of the lumbar stabilization and thoracic mobilization exercises in chronic low back pain patients

Conditions: Chronic Low Back Pain

Summary: chronic low-back pain (clbp) is a heterogeneous group of disorders, which according to the new classification of the international association for pain research (iasp), is recognized as an independent entity and belongs to a mixed type of pain caused by central sensitization , which is present for more than 12 weeks. studies have found that lumbar segmental instability (lsi) is one of the most significant cause of lumbar pain through the movement of each spinal segment where degenerative changes were observed in the discs. the aim of this study was to compare the program of lumbar stabilization exercises in the open and closed kinetic chain, in relation to the program of lumbar stabilization exercises and thoracic mobilization in a closed kinetic chain, to evaluate the clinical efficacy of both exercise programs and determine whether initial pain intensity values and disability levels affect the outcome of patients with chronic low back pain. the study was conducted as randomized, single-blind, controlled trial in 80 chronic low-back pain (clbp) patients of both sexes (35 male, 45 female), average age (48.45 +/- 10.22 years, treated at the rehabilitation clinic "dr. miroslav zotović" in belgrade between june 2017 and march 2018. respondents were divided into two groups of 40 patients by simple randomization. participants were given laser therapy, transcutaneous electrical nerve stimulation (tens) and an eight-week kinesiotherapy that included exercises to strengthen the deep lumbar spine stabilizers. retesting was done after 4 and 8 weeks. patients who performed lumbar stabilization and thoracic mobilization exercises program in a closed kinetic chain had better functional recovery and a significant reduction in pain intensity compared to respondents who performed a lumbar stabilization program in opened and closed kinetic chain.


Eligibility criteria:
inclusion criteria: * patients with lumbar pain present for more than 12 weeks, * pain during changing of the position, * radicular pain. exclusion criteria: * cauda equina syndrome, * ankylosing spondylitis, * thoracic deformities (pectus carinatum, excavatum), * spina bifida, * fractures, * post-operative spinal conditions, * diabetes, * inflammatory processes, * tumors, * pregnancy.
highly cross-linked polyethylene in total knee arthroplasty

Conditions: Knee Arthroplasty, Total

Summary: the aim of this study was to determine clinical and radiographic results after posterior cruciate-substituting total knee arthroplasties with highly cross-linked polyethylene in one knee and compression mold conventional polyethylene in the contralateral knee in the same patients.


Eligibility criteria:
inclusion criteria: * younger than 65 years old * with end stage knee arthritis bad enough for knee replacement exclusion criteria: * inflammatory arthritis * combined foot and ankle disorders. * dementia * patient older than 65 years old.

Keywords: total knee arthroplasty highly cross-linked polyethylene
effects of pre-emptive scalp infiltration with low-dose ketorolac and ropivacaine for postoperative pain

Conditions: Pain; Supratentorial Brain Tumor

Summary: the painless study is a single-center, prospective, randomized, open-label, blinded-endpoint (probe) controlled clinical pilot study to compare the efficacy and safety of pre-emptive scalp infiltration with ropivacaine plus ketorolac and ropivacaine alone for postoperative pain relief in adults undergoing elective supratentorial craniotomies.


Eligibility criteria:
inclusion criteria: * scheduled for elective supratentorial tumour resection; * planned general anaesthesia; * american society of anesthesiologists (asa) physical status i - ii; * age ranging from 18 to 65 years old; * participates required to fix their head in a head clamp intraoperatively; * participates with an anticipated awake within 2 hours after surgery. exclusion criteria: * allergy/intolerance to study drugs including anesthetic drugs, ketorolac and epinephrine; * expected delayed extubation or no plan to extubate; * history of neurosurgeries; * long-term use of analgesics and sedatives (more than 2 weeks) * receiving any painkiller within 24 h before the operation; * extreme body mass index (bmi) (less than 15 or more than 35); * patients with impaired cardiopulmonary; * patients with impaired renal function; * patients with impaired hepatic function; * history of chronic headache; * patients with cognitive deficit; * patients with intellectual disability; * patients with uncontrolled epilepsy; * patients with psychiatric disorders; * difficulties in using pca device * difficulties in understanding the use of numeral rating scale (nrs) ; * patients with suspected intracranial hypertension; * pregnant or at breastfeeding; * infection at the incisional site; * history of radiation therapy and chemotherapy preoperatively * with great likelihood of postoperative radiation therapy and chemotherapy based on preoperative imaging.

Keywords: pre-emptive scalp infiltration ketorolac postoperative pain supratentorial craniotomy a pilot study
the effect of prophylactic anticoagulation on major bleeding events in hospitalized chronic kidney disease and lower limb fracture patients.

Conditions: Fractures, Bone; CKD Stage 4; CKD Stage 3; CKD Stage 5; Enoxaparin Adverse Reaction; Anticoagulant-induced Bleeding; Thromboses, Venous

Summary: the risk of bleeding may be greater than the benefit of antithrombotic protection when prophylactically anticoagulating a patient with a lower limb fracture and advanced ckd. the primary objective was to evaluate the risk major bleeding in patients with lower limb fractures and advance ckd. the secondary objectives were to assess major bleeding in patients with lower limb fractures in ckd stage 4 and 5, thrombosis, death.


Eligibility criteria:
inclusion criteria: * lower limb fracture before surgery * ckd (chonic kidney disease) exclusion criteria: * \<18 years old * kidney transplant * hospital stay \<48 hours * had received any anticoagulant before random assignment to a patient group * had missing data that would render analysis incomplete

Keywords: chronic kidney disease anticoagulation bleeding bone fracture thrombosis
efficacy and safety study of the fixed-dose combination of olmesartan + indapamide when compared to the isolated drugs in the treatment of hypertension.

Conditions: Hypertension; Hypertension,Essential

Summary: phase iii clinical trial, multicenter of non-inferiority, randomized, single-blind evaluation of fixed-dose combination of olmesartan + indapamide compared to the isolated drugs in the treatment of hypertension.

this study is designed for the treatment of essential hypertension. it is performed in participants of both sexes, over 18 years of age, who have essential hypertension with diastolic blood pressure between 90 mmhg and 110 mmhg. the rationale for studying the fixed dose combination is the possibility to enhance compliance and simplify treatment.

Eligibility criteria:
inclusion criteria: * have signed the informed consent form; * participants of both genders aged ≥ 18 years; * essential hypertension based on a diastolic blood pressure (dbp) \> 90 mmhg and \< 110 mmhg; * patients with no treatment or on antihypertensive therapy taking up to two anti-hypertensives; * possibility of discontinuing previous antihypertensive medication during the washout period. exclusion criteria: * essential hypertension based on a diastolic blood pressure (dbp) ≥ 110mmhg and systolic blood pressure (sbp) ≥ 180 mmhg; * secondary hypertension; * participants with body mass index (bmi) \> 35 kg/m2; * non-controlled types 1 and 2 diabetes mellitus (hba1 \> 8,5%); * myocardial infarction, coronary surgery or coronary angioplasty with or without stent placement, in the last 6 months; * unstable angina; * participants with coronary heart disease taking beta-blockers; * clinically manifest heart failure; * history of cardiac arrhythmia; * moderate and severe heart valve disease; * stroke or transient ischemic attack in the last 6 months; * chronic disease of any nature that contraindicates the participant's participation according to the investigator's judgment, in particular renal failure with glomerular filtration rate \< 45 ml/min, serum potassium levels ≥ 5,5 meq/l or ≤ 3,5 meq/l, hepatopathies, or sgot, sgpt or bilirubin levels 3 times above the normal upper limit, and blood dyscrasias; * known allergies or contraindication to the use of the study medication components; * female participants who are pregnant, breastfeeding or who want to become pregnant; * covid-19 symptoms; * post covid-19 syndrome with cardiovascular impairment; * subjects who have participated in other study within the 12 months prior to screening (unless benefit is justified by the researcher).

Keywords: olmesartan olmesartan medoxomil indapamide hypertension
abnormal expression proteins, mitochondrial dna and mirna of irritable bowel syndrome

Conditions: Irritable Bowel Syndrome; Digestive System Diseases; Gastrointestinal Diseases; Intestinal Diseases; Colonic Diseases; Colonic Diseases, Functional

Summary: in the investigators study, the investigators will focus on the screening of the related proteins and mirna to ibs in order to reveal the possible clues or molecular mechanism for this disorder.

for the proteomic procedures, our study groups extracted proteins from the cecum and sigmoid colon samples and ran on the two-dimensional gel electrophoresis (2-de). the proteins on 2-de were visualized by the silver stain, and then gel maps were scanned and analyzed with the image master 2d elite. the obvious abnormal protein spots were identified by the mass spectrometry. western blot 、 immunohistochemistry 、 mrna and mirna were also performed for further verification of the proteins.

Eligibility criteria:
inclusion criteria: * patients with symptoms meeting rome iii criteria for diagnosis of ibs-c and ibs-d exclusion criteria: * patients with organic illnesses or a history of major abdominal surgery * major psychotic episode, mental retardation or dementia * pregnant women and lactational women * postinfectious ibs, pi-ibs

Keywords: ibs proteomics fluorescent quantitation polymerase chain reaction western blot immunohistochemistry staining (ihc) atp content micrna
evaluation of an effectiveness and safety of the electroacupuncture in the management of intractable neuropathic pain

Conditions: Neuralgia; Neuralgia; Postherpetic; Diabetic Neuropathy, Painful; Failed Back Surgery Syndrome

Summary: the investigators will evaluate the effectiveness and safety of acupuncture treatment in refractory neuropathic pain patients.

the purpose of this study was to evaluate the effectiveness of acupuncture treatment in the patients with the following neuropathic pain related syndrome. * postherpetic neuralgia * failed back surgery syndrome * diabetic neuropathy * other peripheral neuropathy patients with refractory neuropathic pain who do not respond to conservative treatment for more than 3 months should be included. acupuncture treatment is maintained for 2 months in oriental medicine hospital. the effect is evaluated through the numeric rating score and the validated questionnaire.

Eligibility criteria:
inclusion criteria: * patients who can adequately write a reportable questionnaire * patients who have been diagnosed with one of the following neuropathic pain disease (postherpetic neuralgia, failed back surgery syndrome, diabetic neuropathy, other peripheral neuropathy) * patients who failed conservative treatment at seoul national university hospital for more than 3 months. * patients with nrs 5 points or more * patients with paindetect score 19 points or more exclusion criteria: * patients with major mental illness * patients with unstable medical conditions * pregnant * patients who received acupuncture treatment at the site within the past month * patients with bleeding tendency * patients taking immunosuppressive drugs

Keywords: neuralgia, acupuncture treatment
single use flexible bronchoscopes in interventional pulmonary procedures

Conditions: Atelectasis; Hemoptysis; Stridor

Summary: single use flexible bronchoscopes have gained popularity in recent years and are becoming technologically more advanced. they are widely accepted and used in everyday practice for simple procedures. the aim of this study is to evaluate single use flexible bronchoscopes in more advanced settings, such as interventional pulmonary procedures.


Eligibility criteria:
inclusion criteria: * all patients requiring an interventional pulmonary procedure during the study period * signed informed consent exclusion criteria: * any patient with a contraindication for rigid and/or flexible bronchoscopy * coagulopathy (pv inr \> 1.3) * thrombocytopenia (\<50x10\*9 or anemia (hgb \<80 g/l) * doac, lmwh or antiplatelet drug therapy * thrombophilia, history of pulmonary embolism or deep vein thrombosis * contraindication for endobronchial application of adrenaline * uncontrolled coronary artery disease, cerebrovascular disease or arrhythmia * uncontrolled pulmonary hypertension * cardiovascular decompensation * severe hypoxia (pao2 \ =60%) * cervical spine instability

Keywords: bronchoscopy single use flexible bronchoscope interventional pulmonology
study of cholesterol levels and types in african americans with type 2 diabetes

Conditions: Type 2 Diabetes; African American; Cholesterol; Lipoprotein; Apolipoprotein

Summary: compared to other races, african-americans with type 2 diabetes have different cholesterol levels, specifically triglycerides and low density lipoprotein. recent data has shown the not only are cholesterol levels important in determining the risk for cardiovascular disease, but the size of the cholesterol particles and surface proteins on the cholesterol particles are also important. the objective of this study is to determine if african-american males with diabetes have different particle size, surface proteins, and cholesterol genetic links than african-american male without diabetes and caucasian-american males with and without diabetes. african-american males with type 2 diabetes and not taking lipid-lowering medications are the current target population. after obtaining an informed consent, a complete medical history will be obtained and subjects will be examined, noninvasively, for physical signs of elevated cholesterol levels. afterwards, blood samples \[one venous puncture, 6 tubes (21 ml total)\] will be obtained. blood samples will be coded, sent to berkeley heart lab and/or clinical laboratory services, and undergo genetic testing at mercer university college of pharmacy and health sciences. confidentiality of the subjects will be explained in the consenting process to the subjects. all subject samples and information will be coded. each subject will be given a subject number upon consenting and this will be used throughout the study. all pertinent information of the subjects will be listed under the designated number, but will not be associated with that patient.


Eligibility criteria:
inclusion criteria: * male * african american by self-report * subjects will be defined as having diabetes if they are diagnosed with diabetes per the american diabetes association guidelines * subjects without diabetes or impaired glucose tolerance will have a fasting blood glucose \<100 mg/dl and/or glycosylated hemoglobin(a1c) \<6.5%. exclusion criteria: * females * self report of race or ethnicity other than african * currently taking any lipid-lowering medications

Keywords: type 2 diabetes african american cholesterol lipoprotein apolipoprotein
requirement of analgesics after two remifentanil dosing regimen in cardiac surgery.

Conditions: Pain

Summary: prospective double blind study comparing two remifentanil dosing protocols (0.1 and 0.3 mcg/kg/min) during cardiac surgery. main outcome measures are postoperative opioid requirements (pca oxycodone) and postoperative pain (vas, verbal rating scale).


Eligibility criteria:
inclusion criteria: * coronary artery bypass grafting patients exclusion criteria: * psychiatric disorders, sleep apnea, cardiac insufficiency

Keywords: pain, postoperative, opioid, pca, cardiac surgery
a study of the safety and pharmacology of sgn-40 administered in combination with bortezomib in patients with relapsed or refractory multiple myeloma

Conditions: Multiple Myeloma

Summary: this is an open-label, multicenter, phase ib study to be conducted at approximately eight sites in europe and the u.s. designed to evaluate the safety, pharmacokinetics, and activity of sgn-40 when combined with bortezomib in patients with multiple myeloma that is relapsed or refractory after at least one prior systemic treatment regimen.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * documented pathologic diagnosis of multiple myeloma that has relapsed or failed to respond after treatment with at least one prior systemic therapy (other than corticosteroid monotherapy) * measurable disease * at least one prior systemic therapy other than single-agent corticosteroids * european union patients must have had prior bone marrow transplant (autologous) or be ineligible for transplant * if previously received bortezomib, demonstration of clinical response of any duration or stable disease with progression-free interval of ≥ 6 months from the start of that therapy * if previously received bortezomib, must have recovered from bortezomib-related toxicities and must have a peripheral neuropathy score of grade ≤ 1, according to the nci ctcae v3.0 * if applicable, completion of autologous transplant ≥ 12 weeks prior to day 1 * discontinuation of previous anticancer or investigational therapy for ≥ 21 days prior to treatment, or ≥ 90 days prior to treatment for previous monoclonal antibody administration exclusion criteria: * prior allogeneic bone marrow transplant * other invasive malignancies within 3 years prior to day 1 except for adequately treated basal cell or squamous cell skin cancer; carcinoma in situ of the cervix, breast, or prostate; or other cancer of which the patient has been disease-free for ≥ 3 years * prior anaphylactic reaction to human immunoglobulin administration * symptomatic hyperviscosity syndrome * active infection requiring parenteral antibiotics within 14 days of day 1 * major surgical procedure or significant traumatic injury within 28 days prior to day 1, or anticipation of need for major surgical procedure during the course of the study * clinically significant cardiac dysfunction or other significant organ dysfunction

Keywords: anti-cd40 myeloma
psilocybin in co-occuring major depressive disorder and borderline personality disorder

Conditions: Borderline Personality Disorder; Major Depressive Disorder

Summary: the primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (mdd) and borderline personality disorder (bpd).

the primary objective of the proposed study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (mdd) and borderline personality disorder (bpd). ten subjects with mdd and bpd will receive a single 25 mg oral dose of psilocybin. the hypothesis to be tested is that psilocybin will result significant reduction in symptoms of both mdd and bpd after 1 week and sustained for 4 weeks compared to baseline (improvement in symptoms will be indicated by lower scores on established outcome measures of mdd and bpd symptoms that have been used in prior studies).

Eligibility criteria:
inclusion criteria: * age 18-65 * diagnosed with current major depressive disorder * montgomery-asberg depression rating scale (madrs) score of \> 20 * diagnosed with borderline personality disorder * borderline personality disorder symptom assessment scale (bpd-sas) score of \> 20 * ability to understand and sign the consent form exclusion criteria: * unstable medical illness based on history or clinically significant abnormalities on baseline physical examination * current pregnancy or lactation, or inadequate contraception in women of childbearing potential * illegal substance use based on urine toxicology screening (except cannabis use) * current or past history of bipolar i disorder, schizophrenia, or schizoaffective disorder * active substance use disorder

Keywords: bpd mdd psilocybin
radiofrequency splanchnic denervation versus retrocrural neurolytic celiac block for pancreatic cancer pain

Conditions: Chronic Pain

Summary: the investigators will evaluate the analgesic efficacy of radiofrequency splanchnic nerve denervation versus neurolytic retrocrural celiac denervation for patients with abdominal pain due to cancer pancreas


Eligibility criteria:
inclusion criteria: * patients with abdominal pain due to cancer pancreas exclusion criteria: * coagulopathy * infection at site of the procedure
pupil dynamics and color vision for the detection of eye diseases

Conditions: Retinitis Pigmentosa; Leber's Hereditary Optic Neuropathy; Stargardt Disease

Summary: the development of new oculometry techniques allows fine and dynamic measurements of pupillary diameter and use in routine clinical practice. the preliminary results obtained with innovative devices on healthy sjuets make it possible to envisage a clinical study on a population of patients suffering from retinal pathologies. this is a "proof of concept" study, which, if the expected results are confirmed, will make it possible to consider a study on a larger population, as well as the industrial development of a commercial device.

this is a single-head study that will take place at the national ophthalmology hospital center (chno) and the vision institute (streetlab) and the total duration of the study is 24 months . it is planned to include 60 participants divided into different groups: * 15 healthy subjects, called controls. * 15 patients with retinitis pigmentosa. * 15 patients with leber's hereditary optic neuropathy. * 15 patients with stargardt's disease. patients will be pre-selected on files at the chno clinical investigation center based on the visual assessment carried out on the day of their arrival, the doctor may suggest that they participate in the study if the inclusion criteria are respected. the control subjects will be recruited thanks to the database of the vision institute at streetlab.

Eligibility criteria:
inclusion criteria: - patients with an understanding of the french language to ensure a perfect understanding of the instructions during evaluations and documents relating to their involvement in the study. visually impaired volunteers: patients must have one of three conditions: retinitis pigmentosa, stargardt disease, leber optic neuropathy. healthy volunteers: * visual acuity of both corrected eyes (glasses) should be higher or equal 8/10th and a normal visual field. * patients should not wear contact lenses (which may interfere with the recording of the pupil and eye movements) exclusion criteria: * pregnant or lactating women will not be able to participate in this research. * participants should not be unable to personally consent. * subjects should not participate in another clinical trial that may interfere with this research. * inability to personally consent. * subjects should not present with degenerative diseases or any other disease that could interfere with the evaluations planned during this study. * the subject follows a drug treatment which can cause visual disturbances, changes in pupillary kinetics or cognitive disturbances. secondary exclusion criteria (at the end of the inclusion visit): * visually impaired subjects and controls for which calibration is not feasible. * patients and control subjects having difficulty maintaining visual fixation. * patients and subjects wearing corrective lenses making it impossible to record oculomotor activity with an infrared camera oculometer.